{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_2009_0239800_A1","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"001-627-505-472-747"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11619,"type":"PATENT","title":"Georgia Institute of Technology - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":6421,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8294,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: georg* inst*
Select more for logical variants. Add to collection.
Select all patents in the collection and expand by simple families. Add to collection. Total patents: 6058
Search Applicants and Owners separately: georg* inst*
Select more for logical variants. Add to collection.
Select all patents in the collection and expand by simple families. Add to collection. Total patents: 6058
administering to a host or patient in need thereof a peptide having at least 97% sequence identity to SEQ ID NO: 1 to reduce chloride transport through a chloride channel."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 4, wherein the chloride channel is a ClC channel."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 5, wherein the chloride channel is ClC-2."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 4, wherein the aberrant ClC channel activity is a result of a disease or disorder selected from the group consisting of cancer, cystic fibrosis, epilepsy, renal tubular disorders, Bartters syndrome, Dent's disease, myotonia, osteopetrosis, Angleman or Prader-Willi, upregulation of chloride channels in glioma cells, diarrhea-predominant inflammatory bowel syndrome, autosomal dominant polycystic kidney disease (ADPKD), excitotoxic neuronal injury, and secretory diarrhea."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["A method for inhibiting overactive chloride channels comprising\n
administering to a host or patient in need thereof an effective amount of a peptide having at least 97% sequence identity to SEQ ID NO: 1 to inhibit or reduce chloride channel activity."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["A method for isolating ClC-2 protein comprising:\n
attaching a peptide having at least 97% sequence identity to SEQ ID NO:1 to a solid support; and\n
contacting the peptide on the solid support with a sample comprising ClC-2 under conditions promoting the interaction of the peptide with ClC-2 to retain ClC-2."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 9, further comprising washing the solid support to remove non-specifically bound components."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 10, further comprising eluting ClC-2 from the solid support."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["A method for stabilizing the conformation of ClC-2 comprising\n
contacting ClC-2 with an effective amount of a peptide having at least 97% sequence identity to SEQ ID NO: 1 to bind and stabilize ClC-2."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 12, wherein the contacting occurs in vitro."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["Use of a polypeptide having at least 97% sequence identity to SEQ ID NO: 1 for the manufacture of a medicament for the treatment of aberrant ClC channel activity."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The use of claim 14, wherein the ClC channel is ClC-2."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["The use of claim 14, wherein the aberrant ClC channel activity is related to a disease or disorder selected from the group consisting of cancer, cystic fibrosis, epilepsy, renal tubular disorders, Bartter's syndrome, Dent's disease, myotonia, osteopetrosis, Angleman or Prader-Willi, upregulation of chloride channels in glioma cells, diarrhea-predominant inflammatory bowel syndrome, autosomal dominant polycystic kidney disease (ADPKD), excitotoxic neuronal injury, and secretory diarrhea."],"number":16,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}